ABSTRACT
Objective This study investigated the genetic and epigenetic mechanisms underlying the comorbidity patterns of five substance dependence diagnoses (SDs; alcohol, AD; cannabis, CaD; cocaine, CoD; opioid, OD; tobacco, TD).
Methods A latent class analysis (LCA) was performed on 31,197 individuals (average age 42±11 years; 49% females) from six cohorts to identify comorbid DSM-IV SD patterns. In subsets of this sample, we tested SD-latent classes with respect to polygenic burden of psychiatric and behavioral traits and epigenome-wide changes in three population groups.
Results An LCA identified four latent classes related to SD comorbidities: AD+TD, CoD+TD, AD+CoD+OD+TD (i.e., polysubstance use, PSU), and TD. In the epigenome-wide association analysis, SPATA4 cg02833127 was associated with CoD+TD, AD+TD, and PSU latent classes. AD+TD latent class was also associated with CpG sites located on ARID1B, NOTCH1, SERTAD4, and SIN3B, while additional epigenome-wide significant associations with CoD+TD latent class were observed in ANO6 and MOV10 genes. PSU-latent class was also associated with a differentially methylated region in LDB1. We also observed shared polygenic score (PGS) associations for PSU, AD+TD, and CoD+TD latent classes (i.e., attention-deficit hyperactivity disorder, anxiety, educational attainment, and schizophrenia PGS). In contrast, TD-latent class was exclusively associated with posttraumatic stress disorder-PGS. Other specific associations were observed for PSU-latent class (subjective wellbeing-PGS and neuroticism-PGS) and AD+TD-latent class (bipolar disorder-PGS).
Conclusions We identified shared and unique genetic and epigenetic mechanisms underlying SD comorbidity patterns. These findings highlight the importance of modeling the co-occurrence of SD diagnoses when investigating the molecular basis of addiction-related traits.
Competing Interest Statement
RP received a research grant from Alkermes outside the scope of the present study. RP and JG are paid for their editorial work on the journal Complex Psychiatry. JG and HRK are holders of U.S. patent 10,900,082 titled: "Genotype-guided dosing of opioid agonists," issued 26 January 2021. HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics. FRW is an employee of Regeneron Pharmaceuticals with no conflict of interest related to any intellectual property of the company. The other authors have no competing interests to report.
Funding Statement
This study is supported by the National Institute on Drug Abuse, R33 DA047527. GAP acknowledges support from the Yale Biological Sciences Training Program (T32 MH014276), Alzheimers Association (AARF-22-967171), NIH National Institute of Aging (K99AG078503), Yale Franke Fellowship in Science & Humanities, and Yale Women Faculty Forum Award. RP acknowledges grants from the National Institute of Mental Health (RF1 MH132337) and One Mind Rising Star Award. JDD acknowledges support by the National Institute on Drug Abuse K01 DA058807. DFL is funded by a Career Development Award from the US Department of Veterans Affairs Office of Research and Development (1IK2BX005058). HK acknowledges support from the Department of Veterans Affairs (VISN 4 MIRECC and I01 BX004820). JLMO acknowledges support from U.S. Department of Veterans Affairs via 1IK2CX002095 and NIDA R21DA050160. JG reports support from the Department of Veterans Affairs (5IO1CX001849-04 and the VISN 1 New England MIRECC) and NIH/NIDA (2R01DA037974, 1R01DA058862-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was conducted under protocols #9809010515 and #0102012183 approved by the institutional review board of the Yale School of Medicine, New Haven, CT, USA. Written informed consent was obtained from each participant enrolled in the Yale-Penn cohort. The study was performed in agreement with the Helsinki Declaration.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data presented are included in the article and its supplemental material.
